OBJECTIVES: Succinic semialdehyde dehydrogenase (SSADH) deficiency is a gamma-aminobutyric acid (GABA) degradative defect. Epilepsy affects half of patients. The murine model is associated with a transition from absence to convulsive seizures in the third week, with fatal status epilepticus. METHODS: The clinical phenotype is reported from a patient database. Flumazenil-Positron Emission Topography (FMZ-PET) and Transcranial Magnetic Stimulation (TMS) were used to study GABA neurotransmission. Electrocorticography, single cell electrophysiology, and radioligand binding studies are reported from animal studies. RESULTS: Generalized seizures predominate, including tonic-clonic, atypical absence, and myoclonic. EEG discharges are typically generalized spike-wave. MRI shows a dentatopallidoluysian pattern. Sudden Unexpected Death in Epilepsy Patients (SUDEP) has occurred and the associated neuropathology reveals chronic excitotoxic injury in gloubus pallidus. Investigations using FMZ-PET and TMS support downregulation of GABA(A) and GABA(B) activity, respectively, in patients. Gamma-hydroxybutyrate (GHB) induces spike-wave discharges in homozygous null mice via GHB and GABA(B)-mediated mechanisms. These resemble absence seizures and are abolished by a GABA(B) receptor antagonist. Decreased binding of GABA(A) and GABA(B) receptor antagonists has been demonstrated in P19 and P14 null mice, respectively. Downregulation of GABA(A) and GABA(B) receptor subunits is observed by P14. GABA(A) and GABA(B) mediated potentials are reduced from P8-P14. CONCLUSION: Generalized epilepsy and epileptiform discharges are characteristic of SSADH deficiency. Spontaneous absence seizures appear in null mice by the third week, which may be induced by GHB or GABA(B) activity. Subsequent overuse dependent downregulation of GABA(A) and GABA(B) receptor activity may be associated with hyperexcitability concomitant with the transition to generalized seizures.
OBJECTIVES: Succinic semialdehyde dehydrogenase (SSADH) deficiency is a gamma-aminobutyric acid (GABA) degradative defect. Epilepsy affects half of patients. The murine model is associated with a transition from absence to convulsive seizures in the third week, with fatal status epilepticus. METHODS: The clinical phenotype is reported from a patient database. Flumazenil-Positron Emission Topography (FMZ-PET) and Transcranial Magnetic Stimulation (TMS) were used to study GABA neurotransmission. Electrocorticography, single cell electrophysiology, and radioligand binding studies are reported from animal studies. RESULTS: Generalized seizures predominate, including tonic-clonic, atypical absence, and myoclonic. EEG discharges are typically generalized spike-wave. MRI shows a dentatopallidoluysian pattern. Sudden Unexpected Death in EpilepsyPatients (SUDEP) has occurred and the associated neuropathology reveals chronic excitotoxic injury in gloubus pallidus. Investigations using FMZ-PET and TMS support downregulation of GABA(A) and GABA(B) activity, respectively, in patients. Gamma-hydroxybutyrate (GHB) induces spike-wave discharges in homozygous null mice via GHB and GABA(B)-mediated mechanisms. These resemble absence seizures and are abolished by a GABA(B) receptor antagonist. Decreased binding of GABA(A) and GABA(B) receptor antagonists has been demonstrated in P19 and P14 null mice, respectively. Downregulation of GABA(A) and GABA(B) receptor subunits is observed by P14. GABA(A) and GABA(B) mediated potentials are reduced from P8-P14. CONCLUSION:Generalized epilepsy and epileptiform discharges are characteristic of SSADH deficiency. Spontaneous absence seizures appear in null mice by the third week, which may be induced by GHB or GABA(B) activity. Subsequent overuse dependent downregulation of GABA(A) and GABA(B) receptor activity may be associated with hyperexcitability concomitant with the transition to generalized seizures.
Authors: P L Pearl; K M Gibson; Z Quezado; I Dustin; J Taylor; S Trzcinski; J Schreiber; K Forester; P Reeves-Tyer; C Liew; S Shamim; P Herscovitch; R Carson; J Butman; C Jakobs; W Theodore Journal: Neurology Date: 2009-08-11 Impact factor: 9.910
Authors: P L Pearl; K M Gibson; M T Acosta; L G Vezina; W H Theodore; M A Rogawski; E J Novotny; A Gropman; J A Conry; G T Berry; M Tuchman Journal: Neurology Date: 2003-05-13 Impact factor: 9.910
Authors: Phillip L Pearl; Sadat Shamim; William H Theodore; K Michael Gibson; Katherine Forester; Susan E Combs; Daniel Lewin; Irene Dustin; Patricia Reeves-Tyer; Cornelis Jakobs; Susumu Sato Journal: Sleep Date: 2009-12 Impact factor: 5.849
Authors: Maneesh Gupta; Rachel Greven; Erwin E W Jansen; Cornelis Jakobs; Boris M Hogema; Wolfgang Froestl; O Carter Snead; Hilke Bartels; Markus Grompe; K Michael Gibson Journal: J Pharmacol Exp Ther Date: 2002-07 Impact factor: 4.030
Authors: Kara R Vogel; Phillip L Pearl; William H Theodore; Robert C McCarter; Cornelis Jakobs; K Michael Gibson Journal: J Inherit Metab Dis Date: 2012-06-28 Impact factor: 4.982
Authors: Phillip L Pearl; John Schreiber; William H Theodore; Robert McCarter; Emily S Barrios; Joe Yu; Edythe Wiggs; Jianping He; K Michael Gibson Journal: Neurology Date: 2014-02-12 Impact factor: 9.910
Authors: Pattaraporn T Chun; Ronald J McPherson; Luke C Marney; Sahar Z Zangeneh; Brendon A Parsons; Ali Shojaie; Robert E Synovec; Sandra E Juul Journal: Dev Neurosci Date: 2015-02-27 Impact factor: 2.984
Authors: Samuel Lapalme-Remis; Evan Cole Lewis; Christine De Meulemeester; Pranesh Chakraborty; K Michael Gibson; Carlos Torres; Alan Guberman; Gajja S Salomons; Cornelis Jakobs; Andre Ali-Ridha; Mahsa Parviz; Phillip L Pearl Journal: Neurology Date: 2015-08-12 Impact factor: 9.910